| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
2,100 |
1,967 |
$381K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
1,846 |
1,635 |
$280K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
3,140 |
2,558 |
$118K |
| 87634 |
|
2,092 |
1,931 |
$85K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
2,028 |
1,871 |
$83K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,726 |
1,520 |
$81K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,698 |
1,249 |
$73K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
2,440 |
2,240 |
$55K |
| 87581 |
|
2,370 |
2,160 |
$53K |
| 87486 |
|
2,144 |
1,936 |
$47K |
| 87640 |
|
2,482 |
2,279 |
$46K |
| 87541 |
|
1,973 |
1,776 |
$43K |
| 87498 |
|
2,137 |
1,930 |
$38K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
3,681 |
3,130 |
$28K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
644 |
611 |
$23K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
826 |
707 |
$18K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,149 |
1,053 |
$16K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
166 |
127 |
$12K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,042 |
1,316 |
$12K |
| 87641 |
|
717 |
619 |
$11K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,325 |
561 |
$9K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
542 |
344 |
$3K |
| 71046 |
Radiologic examination, chest; 2 views |
128 |
100 |
$2K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
21 |
20 |
$682.29 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
12 |
12 |
$518.40 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,052 |
900 |
$431.64 |
| 80051 |
|
25 |
24 |
$168.00 |
| 87807 |
|
32 |
12 |
$99.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
581 |
483 |
$73.74 |
| 3080F |
|
13 |
12 |
$0.00 |
| 36415 |
Collection of venous blood by venipuncture |
2,126 |
1,851 |
$0.00 |
| 3074F |
|
2,186 |
2,029 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
1,599 |
1,515 |
$0.00 |
| 36416 |
|
876 |
815 |
$0.00 |
| 3079F |
|
67 |
66 |
$0.00 |
| G8418 |
Bmi is documented below normal parameters and a follow-up plan is documented |
14 |
13 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
1,609 |
1,471 |
$0.00 |
| 3078F |
|
1,976 |
1,845 |
$0.00 |
| 99072 |
|
1,801 |
1,601 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
3,879 |
3,541 |
$0.00 |
| 87999 |
|
469 |
455 |
$0.00 |
| 3077F |
|
17 |
14 |
$0.00 |